The study led by Daniel Kadouri, an assistant professor of oral biology at the University of Medicine and Dentistry of New Jersey had three major components.
The first established that isolates of two antibiotic-resistant ocular pathogens, Pseudomonas aeruginosa and Serratia marcescens, were all susceptible to being attacked and killed by at least one of two other bacteria, Micavibrio aeruginosavorus and Bdellovibrio baceriovorus.
The latter two bacteria act as predators against the pathogens but are believed to be "good," or non-infectious, bacteria when they exist within the human body, researchers said.
In the third phase, the two "good" predator bacteria were injected into live worms from the species Galleria mellonella, which is well established as a suitable model to test the toxicity of various microbes as well as a live organism's innate immunity to those microbes.
Where injection of the pathogenic bacterium aeruginosa as a positive control was one hundred per cent fatal to the worms, other worms injected with the two "good" predator bacteria had 11-day survival rates between 93.3 and 100 per cent, a strong sign that the "good" bacteria were not toxic to the worms.
"Taken together, our findings leave us confident that, in isolation, pathogenic bacteria are susceptible to successful attack by predator bacteria, predator bacteria do not appear inherently harmful to ocular cells when applied topically, and a live organism can tolerate the predator bacteria well," said Kadouri.
"The time to test all three phenomena simultaneously in the eye tissue of a live organism may now be at hand," Kadouri said.
The current study presents hope that a wide variety of multidrug resistant (MDR) bacteria may be susceptible to attack by predatory bacteria in settings where antibiotic therapy has increasingly failed.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
